Golden Hand Resources Enters Into Collaboration With Scientists at
Tel-Aviv University on Development of Autologous Stem Cell Technology
... Company Names Experienced Biotechnology Executive as President
and CEO of New Venture

TEL AVIV, Israel, Nov. 9 /PRNewswire-FirstCall/ -- Golden Hand
Resources Inc. (OTC Bulletin Board: GDNH), an emerging company in the
cell therapy space, has announced the payment of an initial License
Fee and R&D installment to Ramot, the technology transfer arm of Tel
Aviv University, pursuant to their Research and Licensing Agreement
to collaborate on the development of
cutting-edge technology for differentiation of bone marrow derived
stem cells into functional neuronal-like cells.

To lead the new venture, Golden Hands Resources has named Dr. Yaffa
Beck as its President and Chief Executive Officer.  Dr. Beck has over
22 years experience in the Israeli biotechnology industry and brings
extensive management experience, including financing, operations,
business development, pre-clinical and clinical development.  Most
recently, she served as President
and CEO of VentuRx Holdings Ltd., her own consulting company,
pursuing innovative technologies in the life sciences.  She was co-
founder and COO of D-Pharm Ltd. and also held management positions at
Orgenics Ltd. and Biotechnology General Ltd.  Dr. Beck holds a D.Sc.
from the University of Pretoria, RSA and a Diploma in Management and
Administration from Bradford University (UK).

"I am very excited about joining the company and am looking forward
to a fruitful relationship with the talented researchers at Tel-Aviv
University. I am confident that the pioneering achievements of Dr.
Daniel Offen and Prof. Eldad Melamed can be developed from the lab to
the clinic to bring future benefit to a large number of patients,"
said Beck. "We believe that adult stem cell therapies are the logical
next step in stem cell clinical applications. Stem cells from bone
marrow hold the promise to be just as effective as
embryonic stem cells, without posing the moral or ethical issues
inherent in the use of embryonic tissue. Moreover, by focusing on the
development of NurOwn(TM), autologous cell transplants derived from
the patients' themselves, we can avoid side effects and overcome
immune rejection."

Golden Hand's NurOwn(TM) technology is based on collaboration between
prominent neurologist, Prof. Eldad Melamed, Head of Neurology at
Rabin Medical Center, and expert cell biologist Dr. Daniel Offen, at
the Felsenstein Medical Research Center of Tel-Aviv University. The
proprietary technology, to which Golden Hand has an exclusive
license, involves induction of bone marrow stromal cells to
differentiate into neural-cells, capable of neurotransmitter release.

"We believe that the ability of these cells to reverse Parkinsonian
behaviour upon transplantation into brains of animal models may
translate into an effective therapy for Parkinson patients," said
Prof. Melamed.  "We are pleased to be working with Golden Hand
Resources and for the opportunity to have our initial research
developed into products that can help mankind," said Isaac Kohlberg,
Chief Executive Officer of Ramot. "Also, having worked with  Dr.
Beck, I am confident of her ability to provide the vision and
leadership to lead the company's technology towards clinical
feasibility and commercial viability."

For more information, contact Dr. Yaffa Beck at
[log in to unmask]

About Parkinson's Disease
Parkinson's Disease (PD), which was first described by James
Parkinson in 1817 as "the shaking palsy", is a chronic, progressive
neurodegenerative disorder, affecting the brain cells responsible for
production of dopamine. The symptoms include tremors, rigidity,
slowness of movement and impaired balance. Over four million people
in the developed world, including as many as 1.5 million Americans,
mainly over the age of 65, are diagnosed with PD. That is predicted
to rise by 10% by 2010.  Pharmaceutical treatments of PD with an
estimated combined annual market value of $4 billion, are
insufficient to meet patient needs. The search for more effective
treatments continues.

About Stem Cell Therapy
Stem cells are non-specialized cells with a remarkable potential for
both self-renewal and differentiation into cell types with a
specialized function,such as muscle, blood or brain cells.  Stem
cells may be sourced from fetal or embryonic tissue or from adult
tissue reservoirs such as bone marrow.  Use of embryonic stem cells,
has become the center of significant ethical and moral
debate.  In contrast, use of adult stem cells does not face the same
moral or legal controversy.  Stem cell therapy aims to "cure" disease
by replacing the 'diseased' cells with 'healthy' cells derived from
stem cells. This approach has the potential to revolutionize medicine
and, if successful, the implied commercial opportunities are great.
Currently, both embryonic stem cells (ESC) and adult stem cells (ASC)
are being explored as the potential basis for multiple cell therapy
products.

About Gold Hand Resources:
Golden Hand Resources is an emerging company developing neural-like
stem cell therapeutic products, NurOwn(TM), based on autologous bone
marrow derived stromal cells, for treatment of neurodegenerative
diseases.

Safe Harbor Statement:
Statements in this announcement other than historical data and
information constitute "forward-looking statements" and involve risks
and uncertainties that could cause Golden Hand Resources' actual
results to differ materially from those stated or implied by such
forward-looking statements.  The potential risks and uncertainties
include, among others, risks associated with Golden Hand Resources'
limited operating history, history of losses and expectation to incur
losses for the foreseeable future; need to raise
additional capital to execute on its business plan; dependence on its
license to Ramot's technology and ability to meet its funding and
payment obligations included in such license agreement; ability,
together with its licensor, to adequately protect the NurOwn(TM)
technology; dependence on key executives who have recently joined the
company and on its scientific consultants; ability to
identify, negotiate and successfully implement strategic partnering
relationships; ability to complete clinical trials successfully and
to obtain required regulatory approvals; competition with companies,
some of which have greater resources and experience in developing and
obtaining regulatory approval for treatments in Golden Hand
Resources' market; the limited public trading market for Golden Hand
Resources' stock which may never develop into an active market; and
other factors detailed in Golden Hand Resources' annual report on
From 10-KSB, quarterly reports on Form 10-QSB, current reports on
Form 8-K and other filings with the Securities and Exchange
Commission available at  http://www.sec.gov or by request to the
Company.

SOURCE Golden Hand Resources Inc

SOURCE: PR Newswire (press release)
http://tinyurl.com/4on9u

* * *
Murray Charters <[log in to unmask]>
Please place this address in your address book
Please purge all others

Web site: Parkinsons Resources on the WWWeb
http://www.geocities.com/murraycharters

----------------------------------------------------------------------
To sign-off Parkinsn send a message to: mailto:[log in to unmask]
In the body of the message put: signoff parkinsn